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INTRODUCTION
Hepatitis is inflammation of the liver and can be caused
by a variety of  different viruses. Since the development
of jaundice is characteristic feature of many liver
diseases, a correct diagnosis of underlying cause of
liver diseases can be made by testing patients’ sera for
the presence of  specific anti-viral antigens or antibodies.
Of the many viral causes of viral hepatitis, few are of
great global importance than Hepatitis B virus (HBV).
The HBV infection constitutes a serious public health
problem, affecting approximately 240 million carriers
worldwide. Chronic HBV infection had been found
to significantly elevate the risk for developing liver
cirrhosis and hepatocellular carcinoma1. HBV is the
most common pathogenic infective cause of hepatitis
and affecting millions of people worldwide2.The virus
is endemic throughout the world. It is shed in various
body fluids of infected individuals2.
Infection with HBV leads to a wide spectrum of clinical
presentations ranging from an asymptomatic carrier
state to self-limited acute or fulminant hepatitis to
chronic hepatitis with progression to cirrhosis and
hepatocellular carcinoma. Infection with HBV is one
of the most common viral diseases affecting man. Both
viral factors and the host immune response have been
implicated in the pathogenesis and clinical outcome
of HBV infection3.
The HBV is an Hepadnavirus with a 42nm partially
double stranded DNA composed of a 27nm
nucleocapsid core (HBcAg), surrounded by an outer
lipoprotein coat (also called envelope) containing the
surface antigen (HBsAg). Hepatocytes that are infected
in vivo by hepadnaviruses produce an excess of non-
infectious viral lipoprotein particles composed of
envelope proteins2.The virus consists of a nucleocapsid
and an outer envelope composed mainly of three
Hepatitis B surface antigens (HBsAg) that play a central
role in the diagnosis of HBV infection. The
nucleocapsid contains hepatitis B core antigen (HBcAg),
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ABSTRACT
Background: Changes in immunological response have been reported during
HBV infections, and these changes can be markers for the diagnosis and
prediction of the outcome of infection The aim of this study was to measure
and correlate serum levels of interleukin-2 (IL-2), C-reactive protein (CRP)
Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and HBV
antigens and antibodies in a sample of patients with HBV infection and in
healthy controls
Methods: The study population consisted of 26 patients with hepatitis B
infection (HBsAg seropositive), and 26 apparently healthy (HBsAg
seronegative) participants as controls. Biochemical markers of liver disease
were evaluated by routine methods. Hepatitis B antigens (HBVsAg, HBeAg)
and antibodies (HBsAb, HBeAb, HBcAb) were determined using
immunochromatographic method. Serum concentrations of IL-2, and CRP
were determined using ELISA method.
Results: IL-2 level in HBsAg seropositive patients was found to be lower than
that of control with no statistical significance while CRP level in HBV positive
patients was higher than that of control with no statistical significance. HBV
patients showed statistically significant difference in AST and ALT levels,
compared to healthy controls. A statistically significant value was also observed
between IL-2 and CRP in HBV infected individuals.
Conclusion: The study concluded that deranged ALT and AST values correlate









J.K. Molade1, A.A. Onifade1, M.A. Jimoh2, O.G. Oyero3, I.C. Ahube1, O.K. Olawuyi1 and I. Ayodeji1
1. Department of  Chemical Pathology, College of  Medicine, University of  Ibadan.
2. Department of  Radiation Oncology, College of  Medicine. University of  Ibadan.
3. Insititute of  Advanced Medical Research and Training, College of  Medicine, University of  Ibadan.
Keyword: IL-2, C-reactive protein, Alanine transferase, Aspartate transaminase, Hepatitis B antigens, Hepatitis B antibodies.
Ann Ibd. Pg. Med 2020. Vol.18, No.1 31-36
                                                   Annals of Ibadan Postgraduate Medicine. Vol. 18 No. 1, June 2020   32
a DNA polymerase reverse transcriptase, the viral
genome as well as cellular proteins4.
HBV DNA can be detected in circulation (using PCR)
within 1 month of infection, but it remains at the
relatively low level of 102–104 genome equivalents
per ml for about 6 weeks before the HBV DNA and
the secreted HBV e Antigen (HBeAg) and HBsAg
increase to their peak titres. HBV core antigen
(HBcAg)- specific IgM appears early, and HBcAg-
specific IgG persists for life, irrespective of the
outcome of infection. Approximately 10–15 weeks
after infection, serum Alanine Aminotransferase (ALT)
levels begin to rise, which indicates T-cell-mediated
liver injury5.
C-reactive protein (CRP) is an acute-phase protein that
serves as an early marker of  inflammation or infection.
The protein is synthesized in the liver and it is normally
found at concentrations of less than 10 mg/L in the
blood. During infectious or inflammatory disease states,
CRP levels rise rapidly within the first 6 to 8 hours
and peak at levels of up to 350–400 mg/L after 48
hours6. When the inflammation or tissue destruction is
resolved, CRP levels falls, making it a useful marker
for monitoring disease activity7.
IL-2 has been known for many years as a T cell growth-
promoting factor. The role of  IL-2 in immune
tolerance appears to be twofold8. First, it has been
shown that IL-2 is critical in programming T cells for
activation-induced cell death9. It is likely that this
function of IL-2 is dependent on its ability to increase
surface expression of Fas ligand (FasL) and suppress
expression of the inhibitor of apoptosis10. The
production of IL-2has been found to bereduced in
chronic viral hepatitis B and this has been used to
investigate its immunomodulatory and antiviral effects.
However, the role of these important immuno-
modulators in hepatic injury due to HBV has not been
evaluated in detail11.
MATERIALS AND METHODS
A total of 52 participants were recruited for this study:
Twenty-six (26) were hepatitis B (HBVsAg) positive
patients and twenty-six (26) apparently healthy (non-
Hepatitis B surface antigen) individuals that were
screened and confirmed using ELISA method
participated in this study.
A total of 52 participants comprising 26 cases and 26
controls were recruited for this study. They were
screened for HBVsAg status by immunographic test
and ELISA prior to recruitment. The cases were
HBVsAg positive patients and the controls were
selected by matching and seronegativity for hepatitis
C and E infections (HCV, HEV)
Sample Collection and Storage
10mls of venous blood was carefully drawn into
appropriate sample bottles, spun to separate the serum.
The serum was separated into a plain sterile sample
bottles and stored at -20oC for analysis.
Data Management and Analysis: Data was coded
and entered into the spread sheet. Analysis was using
(SPSS 16.0). Descriptive statistics such as frequency
counts, percentages, mean ± standard deviation was
used to summarize the results. Student t-test was used
to compare groups while Pearson correlation test was
used to determine whether the relationships between
categorical variables are not statistically significant at
Pd” 0.05.
Laboratory Procedure: ELISA method was used
to measured CRP and IL-2 while ALT and AST were
measured spectrophotometrically. Hepatitis B (HBsAb,
HBeAg, HBeAb, HBcAb) serology test was done using
immunochromatic method with a multi HBV test
cassette consisting of  5 chromatographic strips.
RESULT
Table 1 describes the analysis of  mean between cases
and control of all biochemical parameters (mean ±
SD) as well as comparison between the two groups.
There was no significant difference between the C-
reactive protein (CRP) level of hepatitis B positive
patients and the control population (2.96±0.60;
2.68±0.54ng/dl). There was difference seen between
the values of interleukin- 2 (IL-2) in patients and control
samples (1879±1829; 2599±2573pg/ml) with the
control showing a higher value than that of the test.
Values of  Alanine Transaminase (ALT) were higher in
test than in controls (5.07±8.7; 2.76±2.6UI) and
Aspartate Transaminase was considerably higher in test
population than in the control population
(18.32±22.00; 6.90±3.98UI).
Parameters Cases Control F P value
CRP (mg/dl) 2.96±0.60 2.68±0.54 3.60 0.296
IL-2
(pg/mL)
1879±1829 2599±2573 0.22 0.091
ALT (U/I) 5.07±8.7 2.76±2.60 1.78 0.205
AST(U/I) 18.3±22.0 6.9±3.68 3.10 0.015
Table 1: Comparison of  biochemical profiles of
HBsAg seropositive patients and controls
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Using Pearson’s correlation, the levels of  IL-2, CRP,
AST and ALT were compared as represented in Table
2. There was a statistically significant positive correlation
was observed between IL-2 and CRP (r = 0.403).
And a strong statistically significant positive correlation
was observed between ALT and AST (r = 0.850)
Meanwhile, there was a negative correlation between
AST and IL-2 (r = -0.197) but not statistically
significant and also another negative non statistically
significant correlation between ALT and IL-2 (r = -
0.020).
Some of these results have also been represented in
correlation plots; Figure 1 is a correlation plot between
CRP and IL-2 in HBs Agseropositive patients. Figure
4.2 is a correlation plot between AST and ALT in
HBsAg positive patients.
Table 3 shows the result of  the HBV serological test.
The table shows the presence of HBeAb in 24 (92.3%)
patients and its absence in 2 (7.7%) patients this is also
the same with HBcAb with 24 (92.3%) patients positive
and 2 (7.7%) negative. However, all hepatitis B positive
patients (26) showed the absence of both HBeAg and
HBsAb but were seropositive for HBsAg.Table 3.1
Hepatitis B Serological Assay Tests in seronegative
patients (Controls).
Table 4 and 5 showed the comparison of  biochemical
parameters (mean ± SD) with HBeAb and HBcAb
serological test respectively. The mean interleukin-2
(1971.04±1879.82pg/mL) of patients with a positive
HBeAb and HBcAb was observed to be higher than
that of patients with negative HBeAb and HBcAb
(775.00±35.35pg/mL). The mean value of CRP in
HBeAb and HBcAb positive patient (3.00±0.56) has
no significant difference from that of HBeAb and
HBcAb negative patients (2.55±0.35). ALT mean value
was observed to be higher in patients positive for
IL-2 AST CRP ALT

































Table 2: Pearson correlation between biochemical tests
in HBsAg seropositive patients
Figure 1: Correlation pot between CRP and IL-2 in
HBsAg seropositive patients
Figure 2: Correlation Plot between AST and ALT in
HBsAg Seropositive Patients
N = 26 HbsAg HBsAb HBeAg HBeAb HBcAb
POSITIVE 26 (100%) 0 (0%) 0 (%) 24 (92.3%) 24 (92.3%)
NEGATIVE 0(%) 26 (100%) 26 (100%) 2 (7.7%) 2 (7.7%)
Table 3: Hepatitis B serological assay tests in HBsAg seropositive patients
N = 26 HbsAg HBsAb HBeAg HBeAb HBcAb
POSITIVE 0 (%) 0 (0%) 0 (%) 0(%) 0 (%)
NEGATIVE 26(100%) 26 (100%) 26 (100%) 26 (100%) 26 (100%)
HBsAg- Hepatitis B surface Antigen
HBsAb- Hepatitis B surface Antibody
HBeAg- Hpatitis B envelope Antigen
Table 3.1: Hepatitis B serological assay tests in seronegative patients (Controls)
HBeAb- Hepatits B envelope Antibody
HBcAb- Hepatitis B core Antibody
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HBeAb N Mean F P-value
IL2 POS 24 1971.0 ± 1876.8 3.82 0.005*
NEG 2 775.0 ± 35.35
CRP POS 24 3.0 ± 0.56 0.56 0.283
NEG 2 2.55 ± 0.35
ALT POS 24 5.37 ± 9.03 0.87 0.054
NEG 2 1.50 ± 0.71
AST POS 24 19.08 ± 22.90 0.71 0.094
NEG 2 9.50 ± 3.50
TABLE 4: Comparisons of  biochemical parameters and HBeAg serological results in HBsAg seropositive patients
HBcAb N Mean F P-value
IL2 POS 24 1971.0 ± 1876.8 3.82 0.005*
NEG 2 775.0 ± 35.35
CRP POS 24 3.0 ± 0.56 0.56 0.283
NEG 2 2.55 ± 0.35
ALT POS 24 5.37 ± 9.03 0.87 0.054
NEG 2 1.50 ± 0.71
AST POS 24 19.08 ± 22.90 0.71 0.094
NEG 2 9.50 ± 3.50
TABLE 5: Comparisons of  biochemical parameters and Hbcab serological results in hepatitis B positive patients
IL2 AST CRP ALT HBeAb HBsAb HBeAg
IL2 Pearson Correlation 1 -.197 .403 -.020 -.178 .a .a
Sig. (2-tailed) .335 .041* .923 .385 . .
N 26 26 26 26 26 26 26
AST Pearson Correlation -.197 1 .039 .850 -.118 .a .a
Sig. (2-tailed) .335 .849 .000** .567 . .
N 26 26 26 26 26 26 26
CRP Pearson Correlation .403 .039 1 .156 -.219 .a .a
Sig. (2-tailed) .041* .849 .445 .283 . .
N 26 26 26 26 26 26 26
ALT Pearson Correlation -.020 .850 .156 1 -.121 .a .a
Sig. (2-tailed) .923 .000** .445 .557 . .
N 26 26 26 26 26 26 26
HBeAb Pearson Correlation -.178 -.118 -.219 -.121 1 .a .a
Sig. (2-tailed) .385 .567 .283 .557 . .
N 26 26 26 26 26 26 26
HBsAb Pearson Correlation .a .a .a .a .a .a .a
Sig. (2-tailed) . . . . . .
N 26 26 26 26 26 26 26
HBeAg Pearson Correlation .a .a .a .a .a .a .a
Sig. (2-tailed) . . . . . .
N 26 26 26 26 26 26 26
HBcAb Pearson Correlation -.178 -.118 -.219 -.121 1.000 .a .a
Sig. (2-tailed) .385 .567 .283 .557 .000** . .
N 26 26 26 26 26 26 26
TABLE 6: Summary of  pearson correlations between biochemical parameters and serological results
in hepatits B positive patients
*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
a. Cannot be computed because at least one of the variables is constant.
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HBcAb and HBeAb as compared with patients
negative for it (5.37±9.03mIU/mL; 1.50±0.71mIU/
mL). The same trend of higher and lower AST level
was observed for HBcAb and HBeAb positive
(19.0±22.9mIU/mL) and negative (9.50±3.50mIU/
mL) patients respectively.
Table 6 shows the summary correlation of  all analyzed
parameters and serological tests of Hepatitis B positive
patients. A strong statistically significant difference was
observed between Hepatitis B core Antibody (HBcAb)
and Hepatitis B envelope Antibody (HBeAb) (r =
1.000).
A negative non statistically significance was observed
between all measured parameters (IL-2, CRP, AST and
ALT) and both B core Antibody (HBcAb) and
Hepatitis B envelope Antibody (HBeAb) in Hepatitis
B positive patient.
DISCUSSION
Inflammation, fibrosis, regeneration and, ultimately,
cirrhosis are the responses of the liver to chronic
ongoing injuries. IL-2 is produced by T cells that make
up part of  resident lymphoid population in the liver.
C-reactive protein (CRP) is a non-specific marker of
inflammation and a predictor of a coronary heart
disease, cardiovascular disorders, sub-clinical vascular
diseases12.  Levels of CRP raise parallel with the chronic
liver disease progression, such as chronic hepatitis and
liver cirrhosis, as well as before the progression beginning,
therefore it is a useful prognostic parameter13.
It was observed in this study that interleukin 2 (IL 2)
mean was slightly higher in HBsAg seronegative
individuals than in Hepatitis B positive patients,
however there was no statistically significant difference.
This is similar to the observation of  earlier studies that
reported no difference between patients and control
11, 14, 15. However, the results of this study are different
from one which reported that there was a higher
interleukin-2 level in chronic Hepatitis B infection16;
this may not be unconnected with the different assay
method used in both studies.
 This study observed a statistically significant correlation
between interleukin 2 and C-reactive protein. However,
there was no statistically significant difference observed
between CRP level in HBV seropositive and
seronegative participants. The mean CRP of  test
population was slightly higher than that of control
population. This is consistent with previous study13 that
reported that the expression of C- reactive protein in
HBsAg seropositive individuals correlates with
progression of the disease.
ALT and AST levels were both observed to be higher
in test participants than in control, this is similar to the
earlier reported study17. A strong statistically significant
positive correlation was observed between ALT and
AST with AST having higher values (mean) than ALT,
this is consistent with the findings of earlier study in
Hepatitis B infection18.
In this study, serological test of  HBsAg seropositive
patients revealed two persons (7.7%) with (HBsAg+,
HBeAg-, HBeAb-) while the remaining 24 (92.3%) with
HBsAg+, HBeAg- HBeAb+. All test samples were
found to be HBsAb negative. CRP, ALT and AST
levels in sample negative for HBeAb and HBcAb were
observed to be higher than that of  the other patients
and this is similar to findings from earlier reported
studies13, 16. However, IL-2 in patients negative for
HBeAb and HBcAb were observed to be lower than
values of HBeAb and HBcAb positive.
CONCLUSION
This study showed that the increased production of
CRP and liver enzymes (AST and ALT) was due to
ongoing destruction of hepatocytes as the disease
progresses and that interleukin 2 production levels are
reduced thus liver enzymes are still more important in
diagnosis of Hepatitis B infection.
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